Cholangiocarcinoma

This phase 2 basket study investigated the combination of tucatinib and trastuzumab as second-line treatment for patients with HER2-positive biliary tract cancer. Read More ›

To improve survival in patients with biliary tract cancer, researchers are studying combinations of immunotherapy and poly-ADP ribose polymerase inhibitors; the BilT-02 study is summarized. Read More ›

Researchers present preliminary findings from the HERIZON-BTC-01 study, which investigated zanidatamab’s efficacy in patients with HER2-positive biliary tract cancer. Read More ›

In a subanalysis of the STAMP trial, circulating tumor DNA was assessed for its clinical effectiveness in detecting molecular residual disease in patients with cholangiocarcinoma. Read More ›

In patients with biliary tract cancer, EGFR amplifications and FGFR3 fusions may serve as important predictive biomarkers and as potential targets for anticancer therapy in the future. Read More ›

An analysis of circulating tumor DNA–based comprehensive genomic profiling to detect actionable rearrangements in patients with gastrointestinal malignancies was presented by Pashtoon Kasi, MD, MS. Read More ›

Two phase 1a/1b dose-escalation/expansion trials investigated the efficacy and safety of MDM2-p53 antagonist BI 907828 in patients with advanced biliary tract cancer. Read More ›

CTX-009 in combination with paclitaxel showed encouraging efficacy in patients with advanced biliary tract cancer. Read More ›

Gunagratinib is being investigated in an ongoing phase 2a dose-expansion study in patients with cholangiocarcinoma. Read More ›

Results of the SWOG 1815 study failed to demonstrate a benefit with the addition of nab-paclitaxel to gemcitabine/cisplatin (GemCis) versus GemCis alone. Read More ›